69 related articles for article (PubMed ID: 27696389)
21. Investigating linkage to care following community-based screening for hepatitis B virus in rural Senegal: A mixed methods study.
Coste M; Diouf A; Ndong C; Diouf A; Périères L; Nishimwe ML; Bureau M; Ndiaye A; Maradan G; Diallo A; Boyer S;
J Viral Hepat; 2024 Jun; ():. PubMed ID: 38837819
[TBL] [Abstract][Full Text] [Related]
22. Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy.
Lindahl H; Norlin AC; Bergman P
Open Forum Infect Dis; 2023 Nov; 10(11):ofad551. PubMed ID: 38023555
[TBL] [Abstract][Full Text] [Related]
23. Country-Specific Screening, Prevalence, and Immunity Rates for Hepatitis B Infection in a Large US Safety-Net System.
Zhou K; Sumethasorn M; Wong C; Terrault NA
Open Forum Infect Dis; 2024 Jan; 11(1):ofad699. PubMed ID: 38274550
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
Chen MH; Chen MH; Liu CY; Tsai CY; Huang DF; Lin HY; Lee MH; Huang YH
J Infect Dis; 2017 Feb; 215(4):566-573. PubMed ID: 28011918
[TBL] [Abstract][Full Text] [Related]
25. Care for Vulnerable Populations with Chronic Liver Disease: A Safety-Net Perspective.
Wang MC; Bangaru S; Zhou K
Healthcare (Basel); 2023 Oct; 11(20):. PubMed ID: 37893800
[TBL] [Abstract][Full Text] [Related]
26. Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration.
Jasmine Bullard A; Cunningham FE; Volpp BD; Lowy E; Beste LA; Heron BB; Geraci M; Hammond JM; LaPlant K; Stave EA; Turner MJ; O'Leary MC; Kelley MJ; Hunt CM
Hepatol Commun; 2018 Sep; 2(9):1136-1146. PubMed ID: 30202826
[TBL] [Abstract][Full Text] [Related]
27. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network.
Kwak YE; Stein SM; Lim JK
Dig Dis Sci; 2018 Jan; 63(1):61-71. PubMed ID: 29177849
[TBL] [Abstract][Full Text] [Related]
28. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
29. Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for rheumatoid arthritis.
Tien YC; Yen HH; Chiu YM
Clin Exp Rheumatol; 2017; 35(5):831-836. PubMed ID: 28375829
[TBL] [Abstract][Full Text] [Related]
30. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
32. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
[TBL] [Abstract][Full Text] [Related]
33. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
34. Short article: Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
Spinicci M; Emmi G; Dies L; Barilaro A; Vitiello G; Mencarini J; Cavallo A; Bartoloni A; Bartalesi F
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):756-760. PubMed ID: 29649073
[TBL] [Abstract][Full Text] [Related]
35. Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience.
Junus K; Aguilar M; Patel P; Irwin D; Yee S; Liu B; Bhuket T; Wong RJ
Cancer; 2017 Feb; 123(4):650-656. PubMed ID: 27696389
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
